This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.

Acute Migraine

~Estimated

~$10 – $8,750

Kallyope Inc.NCT07674654

Phase 1

A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department

Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acut…

MigraineMigraine DiseaseMigraine in Adults+4 more

~Estimated

~$10 – $6,250

University of South FloridaNCT07667621